News & Events about Praxis Precision Medicines I.
Globe Newswire
2 months ago
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, ...
Globe Newswire
3 months ago
Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in 2H23 Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (mADL) primary ...
Ticker Report
3 months ago
Praxis Precision Medicines, Inc. (NASDAQ:PRAX Get Rating) Equities research analysts at William Blair issued their Q1 2024 earnings estimates for Praxis Precision Medicines in a note issued to investors on Tuesday, February 7th. William Blair analyst M. Minter anticipates that the ...
Globe Newswire
4 months ago
Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following market close on Thursday, February 9 Topline results expected for each of three clinical-stage epilepsy programs in 2023 PRAX-222 first-in-patient EMBRAVE...
Praxis Precision Medicines (NASDAQ:PRAX Get Rating) had its target price boosted by HC Wainwright from $10.00 to $16.00 in a report published on Friday, The Fly reports. The firm currently has a buy rating on the stock. Praxis Precision Medicines Stock Performance Shares of PRAX opened at $4.64 on ...